Ubiquitination of both adeno-associated virus type 2 and 5 capsid proteins affects the transduction efficiency of recombinant vectors

Journal of Virology

Volumn 76, Issue 5, 2002, Pages 2043-2053

  Yan, Ziying ^a   Zak, Roman ^a   Luxton, G W Gant ^a   Ritchie, Teresa C ^a   Bantel Schaal, Ursula ^a   Engelhardt, John F ^a  

^a UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAPSID PROTEIN; HELICASE; LUCIFERASE; PROTEASOME; PROTEASOME INHIBITOR; UBIQUITIN;

ADENO ASSOCIATED VIRUS; ADENO ASSOCIATED VIRUS 2; ADENO ASSOCIATED VIRUS 5; ANIMAL CELL; ARTICLE; CONJUGATION; CONTROLLED STUDY; GENE EXPRESSION; GENE TRANSFER; GENETIC STABILITY; GENETIC TRANSDUCTION; HUMAN; HUMAN CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN DENATURATION; PROTEIN EXPRESSION; PROTEIN PROCESSING; TRANSGENE; VIRION; VIRUS CAPSID; VIRUS GENOME; VIRUS INFECTION; VIRUS RECOMBINATION; WESTERN BLOTTING;

ANIMALS; CAPSID; CELL LINE; CYSTEINE ENDOPEPTIDASES; DEPENDOVIRUS; GENETIC VECTORS; HELA CELLS; HUMANS; MULTIENZYME COMPLEXES; PROTEASOME ENDOPEPTIDASE COMPLEX; RECOMBINATION, GENETIC; TRANSDUCTION, GENETIC; TRANSGENES; UBIQUITIN; VIRION;

EID: 0036171821     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/jvi.76.5.2043-2053.2002     Document Type: Article

References (45)

1. Adeno-associated virus Rep78 protein and terminal repeats enhance integration of DNA sequences into the cellular genome
2. Human adeno-associated virus type 5 is only distantly related to other known primate helper-dependent parvoviruses
3. Several log increase in therapeutic transgene delivery by distinct adeno-associated viral serotype vectors
4. Adeno-associated virus (AAV) type 5 Rep protein cleaves a unique terminal resolution site compared with other AAV serotypes
5. Cloning and characterization of adeno-associated virus type 5
6. Cloning of adeno-associated virus type 4 (AAV4) and generation of recombinant AAV4 particles
7. Recombinant adeno-associated virus type 2, 4, and 5 vectors: Transduction of variant cell types and regions in the mammalian central nervous system
8. Structural and functional heterogeneity of integrated recombinant AAV genomes
9. Circular intermediates of recombinant adeno-associated virus have defined structural characteristics responsible for long-term episomal persistence in muscle
10. Enhancement of muscle gene delivery with pseudotyped AAV-5 correlates with myoblast differentiation
11. A new dual-vector approach to enhance recombinant adeno-associated virus-mediated gene expression through intermolecular cis activation
12. Endosomal processing limits gene transfer to polarized airway epithelia by adeno-associated virus
13. Transduction with recombinant adeno-associated virus for gene therapy is limited by leading-strand synthesis
14. Adeno-associated virus vectors for gene therapy
15. A multicomponent system that degrades proteins conjugated to ubiquitin. Resolution of factors and evidence for ATP-dependent complex formation
16. Impaired intracellular trafficking of adeno-associated virus type 2 vectors limits efficient transduction of murine fibroblasts
17. Adeno-associated virus type 2-mediated gene transfer: Altered endocytic processing enhances transduction efficiency in murine fibroblasts
18. The protein substrate binding site of the ubiquitin-protein ligase system
19. Hybrid vectors based on adeno-associated virus serotypes 2 and 5 for muscle-directed gene transfer
20. Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector
21. DNA helicase-mediated packaging of adeno-associated virus type 2 genomes into preformed capsids
22. Positive and negative autoregulation of the adeno-associated virus type 2 genome
23. Role for highly regulated rep gene expression in adeno-associated virus vector production
24. Site-specific integration by adeno-associated virus
25. Kinetic studies on the inhibition of isopeptidase T by ubiquitin aldehyde
26. Nucleotide sequencing and generation of an infectious clone of adeno-associated virus 3
27. Use of adeno-associated virus as a general transduction vector for mammalian cells
28. Increasing the size of rAAV-mediated expression cassettes in vivo by intermolecular joining of two complementary vectors
29. Mechanisms underlying ubiquitination
30. Human fibroblast growth factor receptor 1 is a co-receptor for infection by adeno-associated virus 2
31. Infectious clones and vectors derived from adeno-associated virus (AAV) serotypes other than AAV type 2
32. Helper-free stocks of recombinant adeno-associated viruses: Normal integration does not require viral gene expression
33. The ubiquitin-proteasome pathway and pathogenesis of human diseases
34. Antiviral activity of the proteasome on incoming human immunodeficiency virus type 1
35. Evidence for covalent attachment of the adeno-associated virus (AAV) rep protein to the ends of the AAV genome
36. The ubiquitin-proteasome system and endocytosis
37. AlphaVbeta5 integrin: A co-receptor for adeno-associated virus type 2 infection
38. Membrane-associated heparan sulfate proteoglycan is a receptor for adeno-associated virus type 2 virions
39. Overcoming adeno-associated virus vector size limitation through viral DNA heterodimerization
40. Binding of adeno-associated virus type 5 to 2,3-linked sialic acid is required for gene transfer
41. Gene therapy vectors based on adeno-associated virus type 1
42. Production of high-titer recombinant adeno-associated virus vectors in the absence of helper adenovirus
43. A myogenic cell line with altered serum requirements for differentiation
44. From the cover: Trans-splicing vectors expand the utility of adeno-associated virus for gene therapy
45. Adeno-associated virus type 5 (AAV5) but not AAV2 binds to the apical surfaces of airway epithelia and facilitates gene transfer